| China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD (NCT06666413) | Genzyme, a Sanofi Company | 2025-05-07 |
| Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) (NCT05164055) | Genzyme, a Sanofi Company | 2022-07-11 |
| China Post-marketing Surveillance (PMS) Study of Aldurazyme® (NCT05134571) | Genzyme, a Sanofi Company | 2021-10-28 |
| China Post-marketing Surveillance (PMS) Study of Fabrazyme® (NCT05054387) | Genzyme, a Sanofi Company | 2021-10-13 |
| Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen (NCT04676373) | Genzyme, a Sanofi Company | 2021-03-10 |
| Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects (NCT05238714) | Genzyme, a Sanofi Company | 2020-05-26 |
| Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (NCT03974113) | Genzyme, a Sanofi Company | 2020-01-28 |
| Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (NCT02855268) | Genzyme, a Sanofi Company | 2019-11-02 |
| Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada (NCT03784898) | Genzyme, a Sanofi Company | 2019-02-08 |
| Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (NCT03754790) | Genzyme, a Sanofi Company | 2019-01-09 |
| Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment (NCT03687333) | Genzyme, a Sanofi Company | 2018-12-04 |
| Effect of Venglustat in Patients With Renal Impairment (NCT03687554) | Genzyme, a Sanofi Company | 2018-10-05 |
| A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (NCT03523728) | Genzyme, a Sanofi Company | 2018-10-04 |
| A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants (NCT06421714) | Genzyme, a Sanofi Company | 2018-08-16 |
| A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (NCT03549871) | Genzyme, a Sanofi Company | 2018-07-25 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors (NCT03417245) | Genzyme, a Sanofi Company | 2018-03-01 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors (NCT03417102) | Genzyme, a Sanofi Company | 2018-02-14 |
| A Study of RG-012 in Subjects With Alport Syndrome (NCT03373786) | Genzyme, a Sanofi Company | 2017-12-22 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (NCT03368664) | Genzyme, a Sanofi Company | 2017-10-23 |
| A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (NCT03019406) | Genzyme, a Sanofi Company | 2017-10-12 |